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BACKGROUND:Disease-specific instruments, commonly incorporated into clinical
trials, provide comprehensive insights into the quality-of-life of patients experi-
encing that disease. However it is not possible to directly elicit preference-based
valuations from such instruments for use in cost-utility analysis. OBJECTIVES: To
provide a mapping algorithm for estimating EQ-5D index scores from the Urinary
Incontinence-specific Quality of Life Questionnaire (I-QOL) based on nationally
representative samples of patients with idiopathic or neurogenic overactive blad-
der (OAB) syndrome using EQ-5D preference valuations based on both the UK and
US general populations. METHODS: Analyses were conducted for 2505 patients
from the Adelphi OAB Disease Specific Programme, a cross-sectional study of pa-
tients consulting with idiopathic or neurogenic OAB, undertaken in the USA and
Europe in 2010. A range of statistical mapping techniques including OLS, CLAD,
Tobit, GLMs, reverse GLMs and reverse two-part GLMs were used. Ten-fold cross
validation techniques were employed to calculate Mean Absolute Error (MAE) and
Root Mean Squared Error (RMSE) goodness of fit statistics. Various predictor lists
together with a method combining stepwise selection with multivariable fractional
polynomial techniques to allow non-linear relationships to feature were pursued.
RESULTS: Choice of predictors was consistent for both the UK and USA EQ-5D
tariffs. For idiopathic, the best model included IQOL Composite Score and age (both
modelled non-linearly). For neurogenic the best model was I-QOL Social Embar-
rassment Score modelled linearly only. Best fit results were better in the idiopathic
(n2351: MAE  0.10. RMSE  0.14) than neurogenic sample (n254: MAE  0.17.
RMSE  0.22). CONCLUSIONS: This research provides algorithms for mapping
EQ-5D index scores from I-QOL allowing calculation of appropriate preference-
based health-related quality-of-life scores for use in cost-effectiveness analyses
when only I-QOL data are available. The strongest results were for idiopathic
patients, but those for neurogenic are consistent with other published mapping
studies.
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OBJECTIVES: To construct and validate a prediction model of preference-adjusted
health status (EQ-5D) for metastatic castrate resistant prostate cancer (CRPC) pa-
tients using FACT-P (Functional Assessment of Cancer Therapy–Prostate), a multi-
dimensional prostate cancer-specific health-related quality of life instrument.
METHODS: Patient-level data were obtained for CRPC patients from the Adelphi
Group Prostate Cancer Disease Specific Program (DSP) data, a multinational cross-
sectional study of prostate cancer patients conducted in France, Germany, Italy,
Spain and UK during 2009 to 2010. EQ-5D and FACT-P were available for a subset of
patients. Country specific utility values were derived from EQ-5D profiles based on
value sets available for 8 countries and the EU. Predictive validity of the FACT-P
subscales and patient demographics for utility was tested using ordinary least
square (OLS), median, Gamma and Tobit multivariate regression models, and pre-
dictive algorithms developed to convert FACT-P to EQ-5D utilities for different
value sets. RESULTS: Values for both FACT-P (mean85.4) and EQ-5D were avail-
able for 291 patients (mean age70.7). A total of 57% of patients were treated with
chemotherapy at the time of assessment, 10% had prior chemotherapy, and 33%
were chemotherapy naive. Mean estimated country-specific utilities varied be-
tween 0.59 (New Zealand) and 0.76 (Germany). OLS and TOBIT regression were the
best-performing models, explaining between 34.6% (Danish) and 46.8% (EU) of the
observed EQ-5D variation. The physical and functional well-being subscales had
the highest explanatory value. The social well-being and prostate cancer specific
subscales, and patient age and BMI did not have statistically significant additional
explanatory value. CONCLUSIONS: The developed algorithms enable to translate
cancer-specific health-related quality of life measures to preference-adjusted
health status in metastatic CRPC patients, taking into account local country-spe-
cific utility weights. The findings will help to develop health status adjustments in
cost-utility analyses used in appraising health care technologies.
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OBJECTIVES: To carry out cost utility analysis, utility values can be derived using
generic preference based measures such as EQ-5D or SF-6D. In some settings ge-
neric measures are not used, and mapping functions are being developed to predict
utility scores from condition specific measures. The aim of this study is to map the
DHP-18 - a diabetes-specific HRQoL patient reported outcome measure - onto
EQ-5D and SF-6D utility scores for type 1 and type 2 diabetes mellitus populations.
METHODS: The data used was pooled from a longitudinal study of quality of life in
diabetes. OLS, GLS and Tobit models regressing DHP dimensions and, separately,
DHP items onto EQ-5D and SF-6D index scores for both type 1 (n236) and type 2
(n2358) diabetes populations were applied. RESULTS: For both the EQ-5D and
SF-6D, the GLS model mapping selected DHP-18 item scores, squared item scores,
age and gender onto the utility index provided the best fit, and this was the case for
both the type 1 and type 2 populations (R2 EQ-5D type 1: 0.516; EQ-5D type 2: 0.290;
SF-6D type 1: 0.647; SF-6D type 2: 0.396). The models under predict utility when the
state is severe and over predict when the state is mild. The error associated with
the models was lower for SF-6D than for EQ-5D due to differences in the range of
the measures. CONCLUSIONS: The DHP-18 items can predict both the EQ-5D and
SF-6D utility scores with acceptable precision with the mapping algorithm for the
SF-6D displaying a higher level of precision. The mapping functions developed
from the models can be used to predict utility scores in settings where the EQ-5D
or SF-6D have not been used alongside the DHP-18. However mapping should be
considered second best in comparison to using generic measures in research
studies.
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OBJECTIVES: We have previously developed an adjusted, limited dependent vari-
able, mixture model (ALDMM) approach for estimating EQ-5D utility values from a
range of covariates which reflects the upper bound, skewness and gaps in the
distribution of EQ-5D. The three class ALDMM has been demonstrated to perform
better than standard approaches on aggregate in a rheumatoid arthritis (RA) data-
set but was not superior at very poor health states. Here we refine the method and
apply it to a much larger RA dataset. METHODS: Using an observational dataset of
RA patients (n16,000) we estimate EQ-5D utility values (UK tariff) as a function of
Health Assessment Questionnaire (HAQ), pain, age and sex. This was done using
linear, Tobit, three and four class ALDMMs. We further adjusted the ALDMM to
account for the lower EQ-5D bound. RESULTS: EQ-5D is estimated as a function of
HAQ, pain and pain2 as well as age and sex. Previous results were replicated at
extremely poor health states in this very large dataset. By including the additional
adjustment for very poor health states, the ALDMM outperforms all others tested in
terms of model fit and appropriateness of the predictions across the entire range of
EQ-5D CONCLUSIONS: The ALDMM approach is designed to appropriately reflect
the range of challenges that arise from the EQ-5D distribution. Standard models are
not as appropriate and fit the data less well. It may be that an additional adjust-
ment to the ALDMM is required to model extremely serious health states, which
are often of critical importance in cost effectiveness models, though the relative
scarcity and credibility of data at this extreme remain a concern.
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OBJECTIVES: Treatments that impact upon survival form a high proportion of the
interventions appraised by the National Institute for Health and Clinical Excellence
(NICE). Survival data are commonly censored and therefore extrapolation is re-
quired to estimate the full impact of the new intervention. There are a range of
approaches for conducting survival analysis in these circumstances, and these can
lead to widely varying survival estimates and incremental cost-effectiveness ratios
(ICERs). We reviewed a subset of NICE Technology Appraisals (TAs) to identify and
analyse methods that are commonly used in practice. METHODS: We identified all
completed NICE TAs that appraised new treatments for advanced and/or meta-
static cancer and analysed methods for estimating survival and justifications for
the chosen approach.RESULTS: By December 2009 NICE had completed 45 TAs that
focussed on advanced and/or metastatic cancer. Parametric models were used in
71% of these. Weibull and exponential models were most commonly used (in 51%
and 44% of the reviewed TAs, respectively), with Gompertz, log-logistic, log normal
and gamma models used infrequently. Piecewise parametric models and other
more flexible methods were seldom used. Justifications of chosen approaches were
not systematic and were usually overly simplistic. CONCLUSIONS: Survival anal-
ysis methods differ significantly across NICE TAs. This is expected because differ-
ent methods are appropriate in different circumstances. However, the majority of
TAs did not take a systematic approach to survival analysis and did not fully justify
chosen methods. Therefore inappropriate methods may have been used. Different
models can lead to large variations in ICERs – for example in NICE TA178 log-logistic
models led to an ICER of £40,000, compared to £75,000 when Gompertz models were
used. Hence it is clearly of great importance to select appropriate models. This
review has contributed to a NICE Technical Support Document on extrapolation
with patient-level data.
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OBJECTIVES: Immunotherapies such as ipilimumab and IL-2 show delayed but
durable response leading to stabilization of symptoms and extended OS after an
initial drop-off in the KM curve. Our objective was to review and challenge cur-
rently available economic modelling methods when applied to such emerging ther-
apies with new mechanisms of action (MoA). METHODS: As alternatives to stan-
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